TENX — TENAX THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 34956 ·
Last close
$11.98
Market Cap
$317.77M
52W High
$16.95
52W Low
$10.37
ADV30
622,249
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -16,573,000 | -15,716,000 | 123,178,000 | 118,755,000 | 8,486,000 |
| Dec 2025 | 0 | — | -16,449,000 | -15,540,000 | 104,227,000 | 97,565,000 | 7,156,000 |
| Sep 2025 | 0 | — | -16,806,000 | -15,804,000 | 102,810,000 | 99,369,000 | 6,599,000 |
| Jun 2025 | 0 | — | -11,792,000 | -10,847,000 | 105,857,000 | 105,462,000 | 2,527,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,800,000
Investing CF
$0
Financing CF
$38,514,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-367,454,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-52,599,000
Pretax Income TTM
$-52,599,000
Interest Exp TTM
$0
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,385,000 | -52,599,000 | 104,227,000 | 7,156,000 | — | -35,800,000 |
| Dec 2024 | 0 | -19,494,000 | -17,602,000 | 96,686,000 | 4,693,000 | — | -14,811,000 |
| Dec 2023 | 0 | -8,234,000 | -7,711,000 | 11,685,000 | 3,587,000 | — | -5,904,000 |
| Dec 2022 | 0 | -11,052,643 | -11,047,895 | 3,404,709 | 1,911,968 | — | -11,388,571 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RZLT | Rezolute, Inc. | $317.76M | $3.30 | — |
| SLN | Silence Therapeutics plc | $313.64M | $6.64 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $312.90M | $5.49 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $327.58M | $3.00 | — |
| IRD | Opus Genetics, Inc. | $332.91M | $4.09 | — |
News headlines (Yahoo Finance, 1h cache)
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 11:00 · Yahoo
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-08 20:05 · Yahoo
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
2026-05-04 11:00 · Yahoo
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
2026-04-22 13:20 · Yahoo
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
2026-04-22 11:00 · Yahoo
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
2026-03-17 13:33 · Yahoo
Tenax Therapeutics: Q4 Earnings Snapshot
2026-03-10 11:24 · Yahoo
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-10 11:00 · Yahoo
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
2026-03-03 12:00 · Yahoo
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
2026-02-15 18:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.